<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03013751</url>
  </required_header>
  <id_info>
    <org_study_id>PHN-Udenafil-03</org_study_id>
    <secondary_id>U01HL068270</secondary_id>
    <nct_id>NCT03013751</nct_id>
  </id_info>
  <brief_title>A Extension Study of Udenafil in Adolescents</brief_title>
  <acronym>FUELExten</acronym>
  <official_title>A Phase III Extension Study of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mezzion Pharma Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mezzion Pharma Co. Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a 12-month (52 week) safety extension study to supplement the FUEL Phase III
      clinical trial to provide safety information regarding the long-term use of udenafil in
      adolescents with single ventricle congenital heart disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open-label extension study. All enrolled subjects will be provided with
      udenafil for the duration of the study. Subjects completing the Phase III FUEL study will be
      eligible for recruitment. Additional subjects will be recruited as needed to ensure a minimum
      of 300 total subjects enroll. Safety, pharmacodynamic and quality of life data will be
      collected and analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (Adverse Events)</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise (Change in maximal oxygen consumption)</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Change in maximal oxygen consumption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echo (Change in myocardial performance Index)</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Change in myocardial performance Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function (Change in log-transformed Reactive Hyperemia Index)</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Change in log-transformed Reactive Hyperemia Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function Health Status (Change in full scale Peds QL)</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Change in full scale Peds QL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers (Change in serum BNP level)</measure>
    <time_frame>52 Weeks</time_frame>
    <description>Change in serum BNP level from baseline to end-of-study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Functional Single Ventricle Heart Disease</condition>
  <arm_group>
    <arm_group_label>Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Udenafil administered for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Udenafil</intervention_name>
    <description>Active drug</description>
    <arm_group_label>Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females with Fontan physiology who participated in the FUEL trial or, if
             they did not participate in FUEL, those who are 12 to less than 19 years of age at
             enrollment.

          2. Participant consent or parental/guardian consent and participant assent.

          3. Participant fluent in English, Spanish, or Korean.

          4. Current anti-platelet or anticoagulant therapy.

        Exclusion Criteria:

          1. Height &lt; 132 cm.

          2. Weight &lt; 40 kg.

          3. Hospitalization for acute decompensated heart failure within the last 12 months.

          4. Current intravenous inotropic drugs.

          5. Undergoing evaluation for heart transplantation or listed for transplantation.

          6. Diagnosis of active protein losing enteropathy or plastic bronchitis within the last
             three years, or a history of liver cirrhosis.

          7. Known Fontan baffle obstruction, branch pulmonary artery stenosis, or pulmonary vein
             stenosis resulting in a mean gradient of &gt; 4 mm Hg between the regions proximal and
             distal to the obstruction as measured by either catheterization or echocardiography.

          8. Single lung physiology.

          9. Maximal VO2 less than 50% of predicted for age and gender at enrollment.

         10. Severe ventricular dysfunction assessed qualitatively by clinical echocardiography
             within six months prior to enrollment.

         11. Severe valvar regurgitation, ventricular outflow obstruction, or aortic arch
             obstruction assessed by clinical echocardiography within six months prior to
             enrollment.

         12. Significant renal, hepatic, gastrointestinal or biliary disorders that could impair
             absorption, metabolism or excretion of orally administered medications.

         13. Inability to complete exercise testing at baseline screening.

         14. History of PDE-5 inhibitor use (with the exception of FUEL participation) within 3
             months before study onset.

         15. Use of any other drug to treat pulmonary hypertension within 3 months before study
             onset.

         16. Known intolerance to oral udenafil.

         17. Frequent use of medications or other substances that inhibit or induce CYP3A4.

         18. Current use of alpha-blockers or nitrates.

         19. Ongoing or planned participation in another research protocol that would either
             prevent successful completion of planned study testing or invalidate its results.

         20. Noncardiac medical, psychiatric, and/or social disorder that would prevent successful
             completion of planned study testing or would invalidate its results.

         21. Cardiac care, ongoing or planned, at a non-study center that would impede study
             completion.

         22. For females: Pregnancy at the time of screening, pregnancy planned before study
             completion, or refusal to use an acceptable method of contraception for study
             duration.

         23. Unable to abstain or limit intake of grapefruit juice during the duration of the
             trial.

         24. Refusal to provide written informed consent/assent.

         25. In the opinion of the primary care physician, the subject is likely to be
             non-compliant with the study protocol.

         26. History of clinically significant thromboembolic event, as adjudicated by study
             Investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Paridon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steve Paridon, MD</last_name>
    <phone>2155903532</phone>
    <email>paridon@email.chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David J Goldberg, MD</last_name>
    <phone>2674268143</phone>
    <email>goldbergda@email.chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Children's Hospital/Children's Heart Center at Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tabitha G Moe, MD</last_name>
      <phone>602-933-3366</phone>
      <email>TMoe@phoenixchildrens.com</email>
    </contact>
    <investigator>
      <last_name>Tabitha G Moe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars/Sinai Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruchira Garg, MD</last_name>
      <phone>310-423-1153</phone>
      <email>Ruchira.Garg@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Ruchira Garg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Davis, MD, PhD</last_name>
      <phone>858-966-5855</phone>
      <email>CDavis@rchsd.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Davis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael V DiMaria, MD</last_name>
      <phone>720-777-4420</phone>
      <email>Michael.DiMaria@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Michael V DiMaria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours Cardiac Center/Alfred I. duPont Hospital for Children</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Shillingford, MD</last_name>
      <phone>302-651-6600</phone>
      <email>Amanda.Shillingford@nemours.org</email>
    </contact>
    <investigator>
      <last_name>Amanda Shillingford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anitha John, MD, PhD</last_name>
      <phone>202-476-2728</phone>
      <email>AnJohn@childrensnational.org</email>
    </contact>
    <investigator>
      <last_name>Anitha John, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins All Children's Heart Institute</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeffrey Jacobs, MD</last_name>
      <phone>727-767-6666</phone>
      <email>JeffJacobs@msn.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Petit, MD</last_name>
      <phone>404-785-1796</phone>
      <email>PetitC@kidsheart.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Petit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children/Herman B. Wells Center for Pediatric Research</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Payne, MD</last_name>
      <phone>317-278-6239</phone>
      <email>RPayne@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Payne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Rhodes, MD</last_name>
      <phone>617-355-3491</phone>
      <email>Jonathan.Rhodes@cardio.chboston.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Rhodes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Congenital Heart Center/C.S. Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-4204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt R Schumacher, MD</last_name>
      <phone>734-764-5176</phone>
      <email>kurts@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Kurt R Schumacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Girish Shirali, MD</last_name>
      <phone>816-234-3947</phone>
      <email>GsSirali@cmh.edu</email>
    </contact>
    <investigator>
      <last_name>Girish Shirali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University St. Louis/St.Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Canter, MD</last_name>
      <phone>314-454-6095</phone>
      <email>Canter@kids.wusti.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Canter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Richmond, MD</last_name>
      <phone>212-305-6575</phone>
      <email>mr2306@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Richmond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byran Goldstein, MD</last_name>
      <phone>513-636-7072</phone>
      <email>bryan.goldstein@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Bryan H Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Goldberg, MD</last_name>
      <phone>267-426-8143</phone>
      <email>goldbergda@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephen Paridon, MD</last_name>
      <phone>2155602226</phone>
      <email>paridon@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Goldberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Paridon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Butts, MD</last_name>
      <phone>843-792-9146</phone>
      <email>Butts@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Butts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Penny, MD, PhD</last_name>
      <phone>832-826-1997</phone>
      <email>DjPenny@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Penny, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Hospital/Dept. of Pediatric Cardiology</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaji C Menon, MD</last_name>
      <phone>801-662-5400</phone>
      <email>Shaji.Menon@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Shaji C Menon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hosptial</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Files, MD</last_name>
      <phone>206-987-1787</phone>
      <email>Matthew.Files@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Files, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salil Grinde, MD</last_name>
      <phone>708-204-2963</phone>
      <email>SGrinde@chw.org</email>
    </contact>
    <investigator>
      <last_name>Salil Grinde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seema Mital, MD</last_name>
      <phone>4168137654</phone>
      <email>Seema.Matal@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Seema Mital, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sejong General Hospital</name>
      <address>
        <city>Bucheon-si</city>
        <state>Gyeonggi-do</state>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seong Ho Kim, MD, PhD</last_name>
      <phone>+82-10-3991-2247</phone>
      <email>shkim24926@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Seong Ho Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Children's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gi Beom Kim, MD</last_name>
      <phone>+82220720266</phone>
      <email>ped9526@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Gi Beom Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Udenafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

